{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:41:38Z","timestamp":1775050898206,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1097\/hjh.0000000000001742","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T03:17:40Z","timestamp":1524453460000},"page":"1736-1742","source":"Crossref","is-referenced-by-count":14,"title":["Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and\/or heart failure"],"prefix":"10.1097","volume":"36","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"K\u00e9vin","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[]},{"given":"Kenneth","family":"Dickstein","sequence":"additional","affiliation":[]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-18-20210208","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2015.03.169","article-title":"Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study","volume":"187","author":"Rossignol","year":"2015","journal-title":"Int J Cardiol"},{"key":"R2-18-20210208","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/HYPERTENSIONAHA.117.09788","article-title":"Visit-to-visit office blood pressure variability and cardiovascular outcomes in SPRINT (Systolic Blood Pressure Intervention Trial)","volume":"70","author":"Chang","year":"2017","journal-title":"Hypertension"},{"key":"R3-18-20210208","doi-asserted-by":"crossref","first-page":"i4098","DOI":"10.1136\/bmj.i4098","article-title":"Blood pressure variability and cardiovascular disease: systematic review and meta-analysis","volume":"354","author":"Stevens","year":"2016","journal-title":"BMJ"},{"key":"R5-18-20210208","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.111.190397","article-title":"Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL","volume":"60","author":"Rossignol","year":"2012","journal-title":"Hypertension"},{"key":"R6-18-20210208","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MNH.0b013e32835b489f","article-title":"Visit-to-visit blood pressure variability and risk for progression of cardiovascular and renal diseases","volume":"22","author":"Rossignol","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R7-18-20210208","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2362.2011.02574.x","article-title":"Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5.5-year prospective analysis","volume":"42","author":"Hsieh","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"R8-18-20210208","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(10)60309-1","article-title":"Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension","volume":"375","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"R9-18-20210208","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","article-title":"Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis","volume":"375","author":"Webb","year":"2010","journal-title":"Lancet"},{"key":"R10-18-20210208","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.07139","article-title":"Visit-to-visit blood pressure variability: an insight into the mechanisms","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension"},{"key":"R11-18-20210208","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/HJH.0000000000000979","article-title":"Visit-to-visit blood pressure variability and future functional decline in old age","volume":"34","author":"Ogliari","year":"2016","journal-title":"J Hypertens"},{"key":"R12-18-20210208","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/HYPERTENSIONAHA.115.06960","article-title":"The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure: findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"68","author":"Kronish","year":"2016","journal-title":"Hypertension"},{"key":"R13-18-20210208","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"R14-18-20210208","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R15-18-20210208","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-9149(98)00898-4","article-title":"Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan","volume":"83","author":"Dickstein","year":"1999","journal-title":"Am J Cardiol"},{"key":"R16-18-20210208","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein E K","year":"2002","journal-title":"Lancet"},{"key":"R17-18-20210208","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1097\/HJH.0b013e32834cf213","article-title":"Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care","volume":"29","author":"Muntner","year":"2011","journal-title":"J Hypertens"},{"key":"R18-18-20210208","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00392-013-0644-4","article-title":"Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET\/TRANSCEND","volume":"103","author":"Lonn","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"R19-18-20210208","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"In Ann Intern Med"},{"key":"R20-18-20210208","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/ejhf.419","article-title":"Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative","volume":"17","author":"von Lueder","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R22-18-20210208","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","article-title":"Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension","volume":"375","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"R23-18-20210208","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/eurheartj\/ehx250","article-title":"Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial","volume":"38","author":"Vidal-Petiot","year":"2017","journal-title":"Eur Heart J"},{"key":"R24-18-20210208","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjcard.2003.12.011","article-title":"Relation between pulse pressure and survival in patients with decompensated heart failure","volume":"93","author":"Aronson","year":"2004","journal-title":"Am J Cardiol"},{"key":"R25-18-20210208","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/eurheartj\/ehi270","article-title":"Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure","volume":"26","author":"Voors","year":"2005","journal-title":"Eur Heart J"},{"key":"R26-18-20210208","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ejcts.2008.01.065","article-title":"Heart rate and pulse pressure at rest are major prognostic markers of early postoperative complications after coronary bypass surgery","volume":"33","author":"Aboyans","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"R27-18-20210208","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R28-18-20210208","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000001742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:27:51Z","timestamp":1621884471000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201808000-00018"}},"subtitle":["findings from the EPHESUS and OPTIMAAL trials"],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0000000000001742","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}